Screening Hallucinogenic Drugs: Systematic Study of Three Behavioral Tests
Overview
Affiliations
The effects of several hallucinogenic and non-hallucinogenic drugs have been studied on three behavioral tests proposed as useful indexes of hallucinogenic activity: "head-twitching" in mice, defecation in an open-field, and suppression of responding on a differential reinforcement of low rates (DRL) schedule of reinforcement. According to the original propositions, after administration of hallucinogenic agents the frequency of head-twitches would increase in mice, the defecation of rats in an open field would decrease without consistent change in ambulation, rearing and grooming, and the responding of rats on a DRL schedule would yield a typical cumulative record pattern. It was found that the head-twitch test was sensitive to mescaline and LSD-25, but not to delta9-THC or to myristicin and elemicin. Besides, the data on interobserver agreement suggested there is a high degree of subjectivity involved in assessing this response. In the open-field test, non-hallucinogenic drugs such as chlorpromazine and apomorphine fell into the hallucinogenic pattern proposed. In addition, the post-injection interval selected seemed to critically affect defecation scores. The DRL "hallucinogenic" pattern occurred nonspecifically after administration of hallucinogenic and non-hallucinogenic drugs. It was concluded that the three tests have limited value for screening purposes.
Kossatz E, Diez-Alarcia R, Gaitonde S, Ramon-Duaso C, Stepniewski T, Aranda-Garcia D Nat Commun. 2024; 15(1):4307.
PMID: 38811567 PMC: 11137019. DOI: 10.1038/s41467-024-48196-2.
Halberstadt A, Luethi D, Hoener M, Trachsel D, Brandt S, Liechti M Psychopharmacology (Berl). 2022; 240(1):115-126.
PMID: 36477925 PMC: 9816194. DOI: 10.1007/s00213-022-06279-2.
Glatfelter G, Chojnacki M, McGriff S, Wang T, Baumann M ACS Pharmacol Transl Sci. 2022; 5(5):321-330.
PMID: 35592434 PMC: 9112414. DOI: 10.1021/acsptsci.1c00237.
The promises and perils of psychedelic pharmacology for psychiatry.
McClure-Begley T, Roth B Nat Rev Drug Discov. 2022; 21(6):463-473.
PMID: 35301459 DOI: 10.1038/s41573-022-00421-7.
Contreras A, Khumnark M, Hines R, Hines D Sci Rep. 2021; 11(1):1925.
PMID: 33479368 PMC: 7820508. DOI: 10.1038/s41598-021-81552-6.